Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Marker Therapeutics ( (MRKR) ).
Marker Therapeutics reported 2025 results highlighting clinical progress for its lead MAR-T candidate MT-601 in the APOLLO Phase 1 lymphoma study, which showed a 66% objective response rate in relapsed non-Hodgkin lymphoma and strong activity in Hodgkin lymphoma, alongside a favorable safety profile and advancement into dose expansion in relapsed DLBCL. The company also underscored promising Nature Medicine data for multi-antigen T cells in pancreatic cancer, continued grant-funded development of its MT-401 off-the-shelf program in AML/MDS, upgraded manufacturing via a Cellipont collaboration, board expansion, and plans to launch a pancreatic cancer trial and deliver further APOLLO data in 2026, positioning the next 12–18 months as a key value-creation window.
The most recent analyst rating on (MRKR) stock is a Sell with a $1.50 price target. To see the full list of analyst forecasts on Marker Therapeutics stock, see the MRKR Stock Forecast page.
Spark’s Take on MRKR Stock
According to Spark, TipRanks’ AI Analyst, MRKR is a Neutral.
MRKR scores low primarily due to ongoing unprofitability and sustained cash burn, despite a relatively low-debt balance sheet. Technicals also lean bearish (price below key moving averages and negative MACD). Valuation provides little support given the unusable P/E and no dividend yield data.
To see Spark’s full report on MRKR stock, click here.
More about Marker Therapeutics
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company developing next-generation, multi-antigen recognizing T cell-based immunotherapies for hematological malignancies and solid tumors. Its lead programs target relapsed lymphomas, pancreatic cancer, and acute myeloid leukemia or myelodysplastic syndrome, with a focus on patients who have limited options after CAR-T therapy.
Average Trading Volume: 317,787
Technical Sentiment Signal: Sell
Current Market Cap: $22.34M
See more insights into MRKR stock on TipRanks’ Stock Analysis page.